Use of Calcium Channel Blockers and Parkinson’s Disease.
Autor: | Pasternak, Björn, Svanström, Henrik, Nielsen, Nete M., Fugger, Lars, Melbye, Mads, Hviid, Anders |
---|---|
Předmět: |
DEMENTIA risk factors
PARKINSON'S disease MORTALITY prevention VASOCONSTRICTORS AGE factors in disease CONFIDENCE intervals STATISTICAL correlation REPORTING of diseases HEALTH status indicators PHARMACY databases LONGITUDINAL method EVALUATION of medical care POISSON distribution PROBABILITY theory RESEARCH funding RELATIVE medical risk RETROSPECTIVE studies DESCRIPTIVE statistics PREVENTION THERAPEUTICS |
Zdroj: | American Journal of Epidemiology; Apr2012, Vol. 175 Issue 7, p627-635, 9p |
Abstrakt: | Experimental evidence and case-control studies suggest that dihydropyridine calcium channel blockers (DiCCBs) may protect against Parkinson’s disease. The authors conducted a historical cohort study in Denmark to investigate the association between DiCCB use and risk of Parkinson’s disease (1998–2006). Individual-level data on filled drug prescriptions, diagnostic information, and covariates were linked between nationwide registries. Among DiCCB users, 173 incident cases of Parkinson’s disease were detected during 461,984 person-years of follow-up, compared with 5,538 cases during 17,343,641 person-years of follow-up among nonusers. After adjustment for age, sex, year, propensity score, and use of other antihypertensive drugs and statins, DiCCB use was associated with a reduced risk of Parkinson’s disease (rate ratio (RR) = 0.71, 95% confidence interval (CI): 0.60, 0.82). This association was not present in patients who had previously used DiCCBs (RR = 1.04, 95% CI: 0.87, 1.24). DiCCB users aged ≥65 years were at lower risk of Parkinson’s disease than DiCCB users aged <65 years (RR = 0.59, 95% CI: 0.40, 0.85). Among patients with Parkinson’s disease, DiCCB use was associated with reduced risk of death (adjusted RR = 0.66, 95% CI: 0.47, 0.91) but not dementia (adjusted RR = 0.97, 95% CI: 0.60, 1.56). In conclusion, DiCCB exposure was associated with a reduced risk of incident Parkinson’s disease, particularly in older patients, and with reduced mortality among patients with Parkinson’s disease. [ABSTRACT FROM PUBLISHER] |
Databáze: | Complementary Index |
Externí odkaz: |